Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Hurler Syndrome Stories

2009-08-19 08:00:00

NOVATO, Calif., Aug. 19 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that data from clinical studies of Kuvan(R) (sapropterin dihydrochloride) and Naglazyme(R) (galsulfase) will be presented at the 11th Annual Meeting of the International Congress of Inborn Errors of Metabolism (ICIEM) in San Diego, California, August 29 through September 2, 2009. "We look forward to a number of abstracts, posters and platform presentations that will highlight a...

2009-07-30 15:05:00

NOVATO, Calif., July 30 /PRNewswire-FirstCall/ -- Financial Highlights ($ in millions, except per share data) Item Q2 2009 Q2 2008 Comparison Total BioMarin Revenue $82.8 29% increase Total Net Product Revenue $81.5 35% increase Naglazyme Net Product Revenue $42.9 22% increase Aldurazyme Net Sales by Genzyme $39.2 1% increase...

2009-07-30 15:00:00

NOVATO, Calif., July 30, /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the United States Patent Office has issued patents covering stable tablet formulation and the approved once daily dosing regimen for Kuvan(R) (sapropterin dihydrochloride) for the treatment of phenylketonuria (PKU). The patent for stable tablet formulation expires in 2025, and the patent for the once daily dosing regimen expires in 2024. "We believe the issuance of these two...

2009-07-13 08:00:00

NOVATO, Calif., July 13 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that patient enrollment has been completed for the Phase I/II clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. The company expects to report initial results in the first half of 2010. "The efficient enrollment of twenty patients...

2009-07-01 08:00:00

NOVATO, Calif., July 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, July 30, at 5:00 p.m. ET (23:00 CET) to discuss second quarter 2009 financial results. U.S. / Canada Dial-in Number: 866.272.9941 International Dial-in Number: 617.213.8895 Participant Code: 45596036 Replay Dial-in Number: 888.286.8010 Replay...

2009-06-16 10:09:00

NOVATO, Calif., June 16 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the temporary interruption of bulk production at Genzyme's Allston Landing manufacturing facility is not expected to have any impact on Aldurazyme supply or revenue to BioMarin or Genzyme. The last Aldurazyme fill at the Allston Landing facility was in September 2008. BioMarin has a total of approximately ten months of vialed inventory on hand, utilizes a second fill finish...

2009-06-10 08:00:00

NOVATO, Calif., June 10 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received notice of priority review status for Kuvan(R) (sapropterin dihydrochloride) as an oral treatment for patients with phenylketonuria (PKU) from Health Canada. Priority review provides for a shortened submission review of 180 days versus the standard twelve months. BioMarin plans to file a marketing application for Kuvan in Canada in the third quarter of 2009, and...

2009-06-10 08:00:00

NOVATO, Calif., June 10 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Steve Aselage, Senior Vice President and Chief Business Officer of BioMarin, will present a company update at the Jefferies Healthcare Conference in New York City on Wednesday, June 17, 2009 at 8:30 a.m. ET. Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be...

2009-05-12 08:00:00

NOVATO, Calif., May 12 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Deutsche Bank 34th Annual Health Care Conference in Boston on Tuesday, May 19, 2009 at 1:55 p.m. ET. Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on...

2009-04-30 15:00:00

Net Product Revenue Increase of 25% Led by Naglazyme International Expansion Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET) NOVATO, Calif., April 30 /PRNewswire-FirstCall/ -- Financial Highlights ($ in millions, except per share data) Item Q1 2009 Q1 2008 Comparison Total BioMarin Revenue $74.0 23% increase Total Net Product Revenue $71.9...